fucosyl-gm1-ganglioside and Colonic-Neoplasms

fucosyl-gm1-ganglioside has been researched along with Colonic-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for fucosyl-gm1-ganglioside and Colonic-Neoplasms

Article	Year
Immunization of mice with fucosyl-GM1 conjugated with keyhole limpet hemocyanin results in antibodies against human small-cell lung cancer cells. Cancer immunology, immunotherapy : CII, 1999, Volume: 48, Issue:9 Fucosyl-GM1 (Fuc-GM1) [Fucalpha1 --> 2Galbeta1 --> 3GalNAcbeta1 --> 4(NeuAcalpha2-3)Galbeta1 --> 4Glcbeta1 --> O-Cer] is a small-cell-lung-cancer (SCLC)-associated ganglioside initially defined by the murine monoclonal antibody F12. On the basis of its known distribution, Fuc-GM1 is a potential target for active immunotherapy in SCLC patients. Fuc-GM1 has been extracted and purified from bovine thyroid. The immunogenicity of Fuc-GM1 was tested in mice either alone, mixed with carrier protein keyhole limpet hemocyanin (KLH) or covalently linked with KLH, plus immunological adjuvant QS-21. The Fuc-GM1-KLH conjugate plus QS-21 adjuvant was found to be optimal. It induced consistent IgM and IgG enzyme-linked immunosorbent assay (ELISA) titers against Fuc-GM1. These antibodies were strongly reactive with the strongly Fuc-GM1-positive rat hepatoma cell line H4-II-E, and they were moderately reactive with the moderately positive human SCLC cell line H146 by flow cytometry and complement-mediated lysis. Both ELISA and fluorescence-activated cell sorting (FACS) reactions were inhibited with Fuc-GM1or H4-II-E but not with the structurally related ganglioside GM1 or Fuc-GM1-negative colon cancer cell line LS-C. On the basis of these results, a vaccine comprising Fuc-GM1-KLH plus QS-21 is being prepared for testing in patients with SCLC. Topics: Adjuvants, Immunologic; Animals; Antibodies, Neoplasm; Cancer Vaccines; Carcinoma, Small Cell; Cattle; Colonic Neoplasms; Complement System Proteins; Cytotoxicity, Immunologic; Enzyme-Linked Immunosorbent Assay; Female; G(M1) Ganglioside; Humans; Immunization; Liver Neoplasms, Experimental; Lung Neoplasms; Mice; Organ Specificity; Rats; Saponins; Tumor Cells, Cultured	1999

Article

Year

Immunization of mice with fucosyl-GM1 conjugated with keyhole limpet hemocyanin results in antibodies against human small-cell lung cancer cells.

Cancer immunology, immunotherapy : CII, 1999, Volume: 48, Issue:9

Fucosyl-GM1 (Fuc-GM1) [Fucalpha1 --> 2Galbeta1 --> 3GalNAcbeta1 --> 4(NeuAcalpha2-3)Galbeta1 --> 4Glcbeta1 --> O-Cer] is a small-cell-lung-cancer (SCLC)-associated ganglioside initially defined by the murine monoclonal antibody F12. On the basis of its known distribution, Fuc-GM1 is a potential target for active immunotherapy in SCLC patients. Fuc-GM1 has been extracted and purified from bovine thyroid. The immunogenicity of Fuc-GM1 was tested in mice either alone, mixed with carrier protein keyhole limpet hemocyanin (KLH) or covalently linked with KLH, plus immunological adjuvant QS-21. The Fuc-GM1-KLH conjugate plus QS-21 adjuvant was found to be optimal. It induced consistent IgM and IgG enzyme-linked immunosorbent assay (ELISA) titers against Fuc-GM1. These antibodies were strongly reactive with the strongly Fuc-GM1-positive rat hepatoma cell line H4-II-E, and they were moderately reactive with the moderately positive human SCLC cell line H146 by flow cytometry and complement-mediated lysis. Both ELISA and fluorescence-activated cell sorting (FACS) reactions were inhibited with Fuc-GM1or H4-II-E but not with the structurally related ganglioside GM1 or Fuc-GM1-negative colon cancer cell line LS-C. On the basis of these results, a vaccine comprising Fuc-GM1-KLH plus QS-21 is being prepared for testing in patients with SCLC.

Topics: Adjuvants, Immunologic; Animals; Antibodies, Neoplasm; Cancer Vaccines; Carcinoma, Small Cell; Cattle; Colonic Neoplasms; Complement System Proteins; Cytotoxicity, Immunologic; Enzyme-Linked Immunosorbent Assay; Female; G(M1) Ganglioside; Humans; Immunization; Liver Neoplasms, Experimental; Lung Neoplasms; Mice; Organ Specificity; Rats; Saponins; Tumor Cells, Cultured

1999